Oric's stock rallies on multiple myeloma deal with Pfizer
Shares of Oric Pharmaceuticals Inc. ORIC, soared about 56% in premarket trading on Thursday, the day after the company said it will collaborate with Pfizer Inc. PFE, to develop a multiple myeloma therapeutic candidate. Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a…#spx #jeffsettleman #phase2 #pfe #pfizer #pfizerinc (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2022 Category: Consumer Health News Source Type: news
Upfront Transplant Prevails Again in Newly Diagnosed Myeloma
(MedPage Today) -- An immunomodulatory-free carfilzomib (Kyprolis)-based triplet regimen failed to prove non-inferior to autologous hematopoietic stem-cell transplantation (HSCT) for the upfront treatment of newly diagnosed multiple myeloma, a... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 20, 2022 Category: Surgery Source Type: news
Renal Impairment Linked to Worse Prognosis in IgD Multiple Myeloma
TUESDAY, Dec. 20, 2022 -- For patients with immunoglobulin D multiple myeloma (IgD MM), those with renal impairment (RI) have poorer prognosis and shorter median survival than those with no renal impairment (no-RI), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2022 Category: Pharmaceuticals Source Type: news
FDA Calls for Withdrawal of Multiple Myeloma Drug Pepaxto FDA Calls for Withdrawal of Multiple Myeloma Drug Pepaxto
The drug was granted an accelerated approval, but a confirmatory phase 3 trial raised concerns about safety after showing higher mortality than in the comparator arm.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Multiple Myeloma Diagnosed More via Emergency Care During COVID Multiple Myeloma Diagnosed More via Emergency Care During COVID
The findings suggest that patients with multiple myeloma may have experienced delays in diagnosis. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 16, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Whole-body PET/CT cuts scan time in melanoma patients
Whole-body PET/CT scans could reduce radiation dose and significantly trim imagin...Read more on AuntMinnie.comRelated Reading:
Whole-body PET/CT for a child: 5 minutes, no sedation
New PET/CT scanners may offer safer imaging in children
AI software could help cut PET scan times in half
PET/CT reveals heart artery inflammation in COVID-19 patients
PET/CT predicts treatment outcomes in myeloma patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 15, 2022 Category: Radiology Source Type: news
Antibody Treatment Makes Inroads Against Multiple Myeloma
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2022 Category: Cancer & Oncology Tags: Oncology, News, Source Type: news
High Response Rates With Talquetamab in Advanced Myeloma High Response Rates With Talquetamab in Advanced Myeloma
The investigational, bispecific T-cell engager homes in on GPRC5D, a novel target unique to malignant plasma cells. It is awaiting approval from the Food and Drug Administration.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Antibody Treatment Makes Inroads Against Multiple Myeloma
MONDAY, Dec. 12, 2022 -- An experimental immunotherapy appears highly effective in attacking bone marrow cancer, with nearly three in four patients responding to the treatment, new clinical trial results show.
The drug, talquetamab, works by... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 12, 2022 Category: General Medicine Source Type: news
New blood cancer therapy treats seven in 10 patients
An antibody infusion could be a game changer for people with persistent multiple myeloma, an aggressive blood cancer. The therapy was successful about 73 per cent of the time. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2022 Category: Consumer Health News Source Type: news
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody. Talquetamab targets both GPRC5D, a novel target on multiple myeloma cells, and CD3 on T cells, activating the body’s immune system to fight this blood cancer.[1] Results from the study suggest patients with relapsed or refractory multiple myeloma who received a median of five prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agen...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Why This Top-Notch IPO Stock Just Broke Out In Bullish Volume
Recent initial public offering Arcellx (ACLX) forged a $325 million multiple myeloma deal with Gilead Sciences (GILD) on Friday, and the IPO stock broke out.X The news comes in lockstep with promising long-term results for Arcellx's multiple myeloma treatment. Every patient with at least one month…#usarcellx #gileadsciences #kitepharma #ipostock #aclx #crs #gilead #myelomadrug #marketsmithcom #arcellx (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2022 Category: Consumer Health News Source Type: news
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma. Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and separately targets CD3 on T cells.[1]“Despite the therapies that have been developed for the treatment of m...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
